Latest Information Update: 04 Oct 2004
At a glance
- Originator Ajinomoto
- Class Antihypertensives
- Mechanism of Action Calcium channel antagonists; Serotonin 2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 01 Oct 2004 Discontinued - Preclinical for Hypertension in Japan (unspecified route)
- 26 Feb 2001 No-Development-Reported for Hypertension in Japan (Unknown route)
- 11 Oct 1996 New profile